Natera, Inc. (NTRA) Announces Results From the SINERGY Trial

Natera, Inc. (NASDAQ:NTRA) is one of the best strong buy healthcare stocks to invest in. On February 24, Natera, Inc. (NASDAQ:NTRA) announced results from the SINERGY trial, a Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma, with the data recently presented in an oral plenary at the 2026 MHNCS. Management reported that 27 patients received initial treatment of either immunotherapy alone or in combination with chemotherapy in the trial, and based on Signatera ctDNA dynamics during treatment, chemotherapy was either escalated or de-escalated.

The study met its primary endpoint and showed that 74% of patients were de-escalated from chemo-immunotherapy to immunotherapy alone, which resulted in a median of 2 chemotherapy cycles across the full cohort and reflects a notable two-thirds reduction from the current standard of care. Natera, Inc. (NASDAQ:NTRA) further reported that the objective response rate came in strong at 63%, comparing favorably to the 36% and 19% ORRs from KEYNOTE-048 patients receiving ICI with and without chemotherapy, respectively. In addition, severe toxicity of grade ≥3 was 48.1%, considerably lower than the 85% and 55% from KEYNOTE-048 patients receiving ICI with and without chemotherapy, respectively.

Natera, Inc. (NASDAQ:NTRA) is a diagnostics company that develops and commercializes molecular testing services, applying its technological services in oncology, women’s health, and organ health. The company provides various diagnostic tests, including Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC), and non-invasive paternity testing (PAT).

While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.